Company intelligence / Profile preview

Pearsanta

Richmond, Virginia, United Statespearsanta.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Pearsanta is advancing a portfolio of non-invasive diagnostic tests using its Mitomic Technology Platform. The lead program, the Mitomic Endometriosis Test (MET), has received IRB approval for a prospective clinical study enrolling up to 1,000 participants to validate its accuracy versus laparoscopic diagnosis. The company also recently acquired proprietary adductomics technology to expand into early cancer risk assessment by detecting DNA damage before mutations occur. Commercialization efforts are underway with strategic partnerships and CLIA/CAP-certified lab infrastructure in place.

Therapeutic areas: OncologyWomen's Health
Modalities: Diagnostic testLiquid biopsyBiomarker-based diagnostics
Industry: Molecular Diagnostics

Drug pipeline

1 asset

AditxtScore

Commercial

Indications: COVID-19, Autoimmune diseases

Partnerships

Evofem Biosciences

Beyond the preview

Go deeper on Pearsanta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearsanta.

Explore the full profile